Loading the records…
Loading the records…
Leidos Holdings ($LDOS) received a $338M delivery order from the NIH National Cancer Institute for operational support in FY26-FY27. This award represents ~2.2% of Leidos' annual revenue and reinforces its role in federal health research services.
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
For $LDOS, this contract adds to a growing backlog in health services, supporting revenue visibility. The stock may see a slight positive drift as the market prices in the award, but given Leidos' size, the impact is modest. No other publicly traded companies are directly affected.
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Direct contract award to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, for operational support at the National Cancer Institute.
Who must act
Department of Health and Human Services / National Institutes of Health awarding to Leidos Biomedical Research Inc.
What happens
$338M added to Leidos' backlog, representing approximately 2.2% of FY2025 revenue ($15.3B).
Stock impact
Leidos' Health segment, which includes biomedical research services, will see a meaningful boost. This contract reinforces Leidos' position as a key NIH contractor, supporting stable revenue growth in a high-margin services area.
Matched on shared policy language across AI analyses, with ticker & timing weight
LEIDOS BIOMEDICAL RESEARCH INC: $485M Department of Health and Human Services Contract
LEIDOS BIOMEDICAL RESEARCH INC: $826M Department of Health and Human Services Contract
LEIDOS BIOMEDICAL RESEARCH INC: $484M Department of Health and Human Services Contract
LEIDOS BIOMEDICAL RESEARCH INC: $484M Department of Health and Human Services Contract
Executive orders & memoranda affecting the same sectors or companies
This proclamation reaffirms U.S. leadership in space exploration, declaring outer space open to development and permanent settlement by American citizens. It sets goals for a return to the Moon by 2028 and a future Mars mission, while emphasizing support for the commercial space industry. The action does not invoke specific legal authorities or direct new funding but signals continued policy focus on space.
The President invokes Section 232 of the Trade Expansion Act to declare that imports of robotics, industrial machinery, and their components threaten national security, and directs the Secretary of Commerce and USTR to negotiate agreements with trading partners to adjust these imports, potentially leading to tariffs or quotas within 180 days.
This proclamation initiates negotiations to adjust imports of wind turbines and their components under Section 232, citing national security concerns including cybersecurity vulnerabilities, radar interference, and grid reliability. It does not immediately impose tariffs but sets the stage for potential trade restrictions, and notes that certain wind turbine components made of aluminum, steel, or copper are already subject to existing tariffs.
Free — no credit card
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →